Moberg Pharma is contemplating a potential bond issue and

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 21, 2016 at 2:30 AM

Moberg Pharma is contemplating a potential bond issue and updates financial targets

STOCKHOLM, January 21st, 2016. Moberg Pharma AB (OMX: MOB) announces that the company intends to issue a bond and has engaged Carnegie Investment Bank and Swedbank as financial advisors. The issue proceeds are intended to be used for general corporate purposes, including accretive add-on acquisitions. Moberg Pharma’s strategy is to generate returns to shareholders by profitable growth of strategic brands, value creating acquisitions and commercialization of pipeline assets. Moberg Pharma’s long-term financial goal is to achieve an EBITDA margin of at least 25 percent. To enable future growth, Moberg Pharma intends to make significant investments during 2016, focusing on strengthening brand platforms for the company’s strategic brands in the U.S., increased international distribution, acquiring additional brands and initiating Phase III studies for MOB-015. As a consequence of decided investments and initiatives, the EBITDA margin in 2016 will be lower than the previously communicated margin of at least 25 percent. The long-term financial goal of achieving an EBITDA margin of at least 25 percent remains. Moberg Pharma’s North American subsidiary markets and sells several strategic brands through its access to all major retailers and the company’s products are available at more than 30,000 points-of-sale in the U.S. In 2016, Moberg Pharma plans to invest in these brands through strengthened positioning and new marketing campaigns based on comprehensive market research. In the last few years, Moberg Pharma has completed four acquisitions, primarily in the U.S., with a total acquisition volume of approximately $35 million. The company continuously evaluates potential acquisitions and intends to increase its acquisition activities going forward focusing on brands and products for which existing infrastructure and sales channels can be utilized. In addition to its commercial operations, Moberg Pharma sees significant potential for value creation by developing MOB-015 through Phase III. MOB-015 peak sales potential is estimated to $250–500 million annually in the rapidly growing market for nail fungus drugs. “Moberg Pharma has in five years grown from zero to close to SEK 300 million in revenue and created a profitable business. We are in a position to strengthen the company and create considerable value for our shareholders. Short-term, we make significant investments while maintaining our long-term financial goal of achieving an EBITDA margin of at least 25 percent”, says Peter Wolpert, CEO Moberg Pharma. As a part of this development, Moberg Pharma evaluates the possibility to utilize its strong balance sheet and diversify its financing by turning to the Nordic corporate bond market as a potential financing source. The issue proceeds from a potential bond issue will be used for general corporate purposes, including accretive add-on acquisitions. Carnegie Investment Bank and Swedbank have been engaged as financial advisors and Gernandt & Danielsson as legal advisor to evaluate the Company’s potential issuance of a corporate bond on the Nordic corporate bond market. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 am (CET) on January 21, 2016. For additional information contact: Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se About Moberg Pharma AB (publ) Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further information, please visit: www.mobergpharma.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Striveworks: Boosting Army's AI Edge in Indo-Pacific

The world keeps marching forward, and here’s Striveworks stepping up to the plate with another big move in the military tech space. This isn't your average partnership renewal; this involves a five-year, $200 million deal to enhance battlefield AI as the U.S. Army hones its modern warfare edge in the Indo-Pacific. Now, this isn't just a battle of strategies but a battle...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Newfold Digital Revamps Leadership for Growth Surge

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...